ProfileGDS5678 / 1441320_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 68% 63% 67% 62% 63% 63% 66% 67% 64% 64% 66% 62% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8413664
GSM967853U87-EV human glioblastoma xenograft - Control 24.1663368
GSM967854U87-EV human glioblastoma xenograft - Control 33.791363
GSM967855U87-EV human glioblastoma xenograft - Control 44.1167467
GSM967856U87-EV human glioblastoma xenograft - Control 53.6579562
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8286163
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8304163
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0222166
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1132867
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8402964
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8295664
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0151166
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6960162
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7606763